...
首页> 外文期刊>Medical science monitor : >Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease
【24h】

Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease

机译:Graves病中的纤溶酶原激活物(组织型t-PA,尿激酶u-PA型)和纤溶酶原激活物抑制剂1(PAI-1)

获取原文

摘要

Haemostatic disturbances are observed in thyroid diseases. The fibrinolytic system reaction is suspected to be the cause. There are few data about the nature of fibrinolytic changes in the serum of patients suffering from Graves disease. The aim of our work was to study serum fibrinolytic system changes in Graves disease due to the concentration of plasminogen activators type of tissue (t-PA) and urokinase (u-PA) and plasminogen activator inhibitor type 1 (PAI-1). The study was performed on 33 patients (F/M 29/4, mean aged 35.0 years) with Graves disease and on 34 healthy volunteers(F/M 28/6, mean age: 33.7 years). Graves disease was diagnosed on the basis of clinical and laboratory evidence of thyrotoxicosis, diffuse goitre and absence of other symptoms of thyrotoxicosis. In the citric blood plasma the concentrations of tissue (t-PA) and urokinase (u-PA) plasminogen activators, and plasminogen activator inhibitor type 1 (PAI-1) antigen were determined using ELISA - test (Biopol, Sweden). The individual values of t-PA Ag and PAI-1 Ag in patients with Graves disease were ranged much wider than in control group and the concentration of antigens reached the highest values in severalcases. Mean concentrations of t-PA, u-PA and PAI-1 antigen in blood plasma of patients were significantly increased comparing to the control group. The hyperthyroid goitre in patients suffering from Graves disease seems to be the source of plasminogen activators (t-PA, u-PA) detected in the blood plasma.
机译:在甲状腺疾病中观察到止血障碍。纤溶系统反应被怀疑是原因。关于格雷夫斯病患者血清中纤维蛋白溶解变化的性质的数据很少。我们的工作目的是研究由于纤溶酶原激活物类型的组织(t-PA)和尿激酶(u-PA)和纤溶酶原激活物抑制剂1型(PAI-1)的浓度而导致Graves病的血清纤溶系统变化。这项研究是针对33位Graves病患者(F / M 29/4,平均年龄35.0岁)和34位健康志愿者(F / M 28/6,平均年龄:33.7岁)进行的。 Graves病是根据甲状腺毒症,弥散性甲状腺肿和没有其他甲状腺毒症症状的临床和实验室证据诊断出来的。在柠檬血浆中,使用ELISA-test(Biopol,瑞典)确定组织(t-PA)和尿激酶(u-PA)纤溶酶原激活物以及1型纤溶酶原激活物抑制剂的浓度。 Graves病患者的t-PA Ag和PAI-1 Ag的个体值范围比对照​​组大得多,并且抗原的浓度在某些情况下达到最高值。与对照组相比,患者血浆中t-PA,u-PA和PAI-1抗原的平均浓度显着增加。患有Graves病的患者甲状腺功能亢进症似乎是血浆中检出的纤溶酶原激活物(t-PA,u-PA)的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号